Clozapine vs Risperidone (Uzedy)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Clozapine
Marketed by HLS Therapeutics Inc.
NCT00250575 · Phase 3 · completed
The study was open-label, single-arm, and had no placebo or active comparator; all 43 participants received clozapine. Its primary measures focused on hematological tests, blood-related adverse events, and monitoring-system compliance rather than a clinical symptom endpoint, and no results are posted.
Next expected readout: April 2027 · NCT04580134 (registry estimate)
Reported efficacy
Treatment efficacy rate (baseline,0.5 months,1 months, 2 months,4 months , 6 months , 8 months and 12 months); All-cause dropout rate (baseline,0.5 months,1 months, 2 months,4 months , 6 months , 8 months and 12 months): Primary 1, symptomatic response (40% or more PANSS total reduction) in phase 2 among 111 re-randomized nonresponders: clozapine 62.5% (20/32) vs amisulpride 44.7% (17/38) vs olanzapine 31.7% (13/41) (chi-square 6.9; P=.03), met. Primary 2, time to all-cause discontinuation: the paper reports no clear difference between treatment groups, missed. (mixed)
Result source: NCT03510325
Risperidone (Uzedy)
Marketed by Teva Pharmaceutical Industries and partners
NCT03503318 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial with 544 participants assigned to placebo, monthly TV-46000, or every-two-month TV-46000. The hard clinical primary endpoint was time to impending relapse, and it was statistically significantly favorable for both monthly treatment (13/183 vs 53/181; p<0.0001) and every-two-month treatment (23/179 vs 53/181; p<0.0001).
Reported efficacy
Time to Impending Relapse (Number of Participants With Impending Relapse) for Intent-to-treat [ITT] Analysis Set (From randomization up to 108 weeks): Time to Impending Relapse (Number of Participants With Impending Relapse) for Intent-to-treat [ITT] Analysis Set (From randomization up to 108 weeks): TV-46000 q1m 13/183 | TV-46000 q2m 23/179 vs Placebo 53/181 (met)
Result source: NCT03503318
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.
| Key endpoint | Clozapine | Risperidone (Uzedy) |
|---|---|---|
| PANSS total, change | —Not posted · NCT00649844 | —Not posted · NCT00159770 |
| CGI-S, change | —Not posted · NCT00649844 | —Not posted · NCT00159770 |
| PANSS response | —Not posted · NCT00649844 | —Not posted · NCT00159770 |
| PSP, change | —Not posted · NCT00649844 | —Not posted · NCT00159770 |
| Relapse (% of patients) | —Not posted · NCT00649844 | 7.1% vs 29.3%−22.2 vs placeboNCT035033187 other results
|
PANSS total, change
- Clozapine
- —Not posted · NCT00649844
- Risperidone (Uzedy)
- —Not posted · NCT00159770
CGI-S, change
- Clozapine
- —Not posted · NCT00649844
- Risperidone (Uzedy)
- —Not posted · NCT00159770
PANSS response
- Clozapine
- —Not posted · NCT00649844
- Risperidone (Uzedy)
- —Not posted · NCT00159770
PSP, change
- Clozapine
- —Not posted · NCT00649844
- Risperidone (Uzedy)
- —Not posted · NCT00159770
Relapse (% of patients)
- Clozapine
- —Not posted · NCT00649844
- Risperidone (Uzedy)
- 7.1% vs 29.3%−22.2 vs placeboNCT03503318
7 other results
- 12.8% vs 29.3% NCT03503318
- 0.1% vs 0.3% NCT03503318
- 0.1% vs 0.3% NCT03503318
- 7.1% vs 29.3% NCT03503318
- 13.3% vs 29.3% NCT03503318
- 7.1% vs 29.3% NCT03503318
- 12.8% vs 29.3% NCT03503318
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Clozapine: 3 of 4 rows · Risperidone (Uzedy): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Clozapine | Risperidone (Uzedy) |
|---|---|---|
| Dropout rate | 41.7%a NCT01639872 · Phase 4 · registry result, not featured evidence show 2 more results0% NCT00498550 · Phase 4 · registry result, not featured evidence 17.2% NCT02404155 · Phase na · registry result, not featured evidence | 21.3%q1ma NCT03503318 · Phase 3 · monotherapy show 3 more results22.2%q2m NCT03503318 · Phase 3 · monotherapy 22.4%q1m NCT03893825 · Phase 3 · monotherapy 24.7%q2m NCT03893825 · Phase 3 · monotherapy |
| Discontinued due to AEs | —a NCT01639872 · Phase 4 · registry result, not featured evidence show 2 more results— NCT00498550 · Phase 4 · registry result, not featured evidence — NCT02404155 · Phase na · registry result, not featured evidence | 2.2%q1ma NCT03503318 · Phase 3 · monotherapy show 3 more results1.1%q2m NCT03503318 · Phase 3 · monotherapy 0%q1m NCT03893825 · Phase 3 · monotherapy 1.2%q2m NCT03893825 · Phase 3 · monotherapy |
| Serious AEs | 13%a NCT01639872 · Phase 4 · registry result, not featured evidence show 2 more results26.7% NCT00498550 · Phase 4 · registry result, not featured evidence 6.9% NCT02404155 · Phase na · registry result, not featured evidence | 4.4%q1ma NCT03503318 · Phase 3 · monotherapy show 3 more results5.6%q2m NCT03503318 · Phase 3 · monotherapy 4.7%q1m NCT03893825 · Phase 3 · monotherapy 6.8%q2m NCT03893825 · Phase 3 · monotherapy |
| Most frequent reported AEs | a other-sialorrhea 43.5% weight gain 30.4% sedation 21.7% NCT01639872 · Phase 4 · registry result, not featured evidence show 2 more resultsgastrointestinal disorder - other: hypersalivation 66.7% somnolence 60% weight gain 40% NCT00498550 · Phase 4 · registry result, not featured evidence salivation 68.2% sedation 52.9% malaise 52.6% NCT02404155 · Phase na · registry result, not featured evidence | q1ma injection site nodule 6.6% (placebo 3.4%) insomnia 6.6% (placebo 5.6%) injection site pruritus 5.5% (placebo 2.2%) NCT03503318 · Phase 3 · monotherapy show 3 more resultsq2m injection site nodule 7.2% (placebo 3.4%) weight increased 7.2% (placebo 3.4%) injection site pain 6.7% (placebo 6.1%) NCT03503318 · Phase 3 · monotherapy |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Clozapine
Risperidone (Uzedy)
show 7 more results
show 1 more result
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Clozapine's landscape · Risperidone (Uzedy)'s landscape